Cargando…

Virtual Clinical Trials Guided Design of an Age-Appropriate Formulation and Dosing Strategy of Nifedipine for Paediatric Use

The rapid onset of action of nifedipine causes a precipitous reduction in blood pressure leading to adverse effects associated with reflex sympathetic nervous system (SNS) activation, including tachycardia and worsening myocardial and cerebrovascular ischemia. As a result, short acting nifedipine pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Dilawar, Badhan, Raj, Kirby, Daniel J., Bryson, Simon, Shah, Maryam, Mohammed, Afzal Rahman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961156/
https://www.ncbi.nlm.nih.gov/pubmed/36839878
http://dx.doi.org/10.3390/pharmaceutics15020556
_version_ 1784895685591564288
author Khan, Dilawar
Badhan, Raj
Kirby, Daniel J.
Bryson, Simon
Shah, Maryam
Mohammed, Afzal Rahman
author_facet Khan, Dilawar
Badhan, Raj
Kirby, Daniel J.
Bryson, Simon
Shah, Maryam
Mohammed, Afzal Rahman
author_sort Khan, Dilawar
collection PubMed
description The rapid onset of action of nifedipine causes a precipitous reduction in blood pressure leading to adverse effects associated with reflex sympathetic nervous system (SNS) activation, including tachycardia and worsening myocardial and cerebrovascular ischemia. As a result, short acting nifedipine preparations are not recommended. However, importantly, there are no modified release preparations of nifedipine authorised for paediatric use, and hence a paucity of clinical studies reporting pharmacokinetics data in paediatrics. Pharmacokinetic parameters may differ significantly between children and adults due to anatomical and physiological differences, often resulting in sub therapeutic and/or toxic plasma concentrations of medication. However, in the field of paediatric pharmacokinetics, the use of pharmacokinetic modelling, particularly physiological-based pharmacokinetics (PBPK), has revolutionised the ability to extrapolate drug pharmacokinetics across age groups, allowing for pragmatic determination of paediatric plasma concentrations to support drug licensing and clinical dosing. In order to pragmatically assess the translation of resultant dissolution profiles to the paediatric populations, virtual clinical trials simulations were conducted. In the context of formulation development, the use of PBPK modelling allowed the determination of optimised formulations that achieved plasma concentrations within the target therapeutic window throughout the dosing strategy. A 5 mg sustained release mini-tablet was successfully developed with the duration of release extending over 24 h and an informed optimised dosing strategy of 450 µg/kg twice daily. The resulting formulation provides flexible dosing opportunities, improves patient adherence by reducing frequent administration burden and enhances patient safety profiles by maintaining efficacious levels of consistent drug plasma levels over a sustained period of time.
format Online
Article
Text
id pubmed-9961156
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99611562023-02-26 Virtual Clinical Trials Guided Design of an Age-Appropriate Formulation and Dosing Strategy of Nifedipine for Paediatric Use Khan, Dilawar Badhan, Raj Kirby, Daniel J. Bryson, Simon Shah, Maryam Mohammed, Afzal Rahman Pharmaceutics Article The rapid onset of action of nifedipine causes a precipitous reduction in blood pressure leading to adverse effects associated with reflex sympathetic nervous system (SNS) activation, including tachycardia and worsening myocardial and cerebrovascular ischemia. As a result, short acting nifedipine preparations are not recommended. However, importantly, there are no modified release preparations of nifedipine authorised for paediatric use, and hence a paucity of clinical studies reporting pharmacokinetics data in paediatrics. Pharmacokinetic parameters may differ significantly between children and adults due to anatomical and physiological differences, often resulting in sub therapeutic and/or toxic plasma concentrations of medication. However, in the field of paediatric pharmacokinetics, the use of pharmacokinetic modelling, particularly physiological-based pharmacokinetics (PBPK), has revolutionised the ability to extrapolate drug pharmacokinetics across age groups, allowing for pragmatic determination of paediatric plasma concentrations to support drug licensing and clinical dosing. In order to pragmatically assess the translation of resultant dissolution profiles to the paediatric populations, virtual clinical trials simulations were conducted. In the context of formulation development, the use of PBPK modelling allowed the determination of optimised formulations that achieved plasma concentrations within the target therapeutic window throughout the dosing strategy. A 5 mg sustained release mini-tablet was successfully developed with the duration of release extending over 24 h and an informed optimised dosing strategy of 450 µg/kg twice daily. The resulting formulation provides flexible dosing opportunities, improves patient adherence by reducing frequent administration burden and enhances patient safety profiles by maintaining efficacious levels of consistent drug plasma levels over a sustained period of time. MDPI 2023-02-07 /pmc/articles/PMC9961156/ /pubmed/36839878 http://dx.doi.org/10.3390/pharmaceutics15020556 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Khan, Dilawar
Badhan, Raj
Kirby, Daniel J.
Bryson, Simon
Shah, Maryam
Mohammed, Afzal Rahman
Virtual Clinical Trials Guided Design of an Age-Appropriate Formulation and Dosing Strategy of Nifedipine for Paediatric Use
title Virtual Clinical Trials Guided Design of an Age-Appropriate Formulation and Dosing Strategy of Nifedipine for Paediatric Use
title_full Virtual Clinical Trials Guided Design of an Age-Appropriate Formulation and Dosing Strategy of Nifedipine for Paediatric Use
title_fullStr Virtual Clinical Trials Guided Design of an Age-Appropriate Formulation and Dosing Strategy of Nifedipine for Paediatric Use
title_full_unstemmed Virtual Clinical Trials Guided Design of an Age-Appropriate Formulation and Dosing Strategy of Nifedipine for Paediatric Use
title_short Virtual Clinical Trials Guided Design of an Age-Appropriate Formulation and Dosing Strategy of Nifedipine for Paediatric Use
title_sort virtual clinical trials guided design of an age-appropriate formulation and dosing strategy of nifedipine for paediatric use
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961156/
https://www.ncbi.nlm.nih.gov/pubmed/36839878
http://dx.doi.org/10.3390/pharmaceutics15020556
work_keys_str_mv AT khandilawar virtualclinicaltrialsguideddesignofanageappropriateformulationanddosingstrategyofnifedipineforpaediatricuse
AT badhanraj virtualclinicaltrialsguideddesignofanageappropriateformulationanddosingstrategyofnifedipineforpaediatricuse
AT kirbydanielj virtualclinicaltrialsguideddesignofanageappropriateformulationanddosingstrategyofnifedipineforpaediatricuse
AT brysonsimon virtualclinicaltrialsguideddesignofanageappropriateformulationanddosingstrategyofnifedipineforpaediatricuse
AT shahmaryam virtualclinicaltrialsguideddesignofanageappropriateformulationanddosingstrategyofnifedipineforpaediatricuse
AT mohammedafzalrahman virtualclinicaltrialsguideddesignofanageappropriateformulationanddosingstrategyofnifedipineforpaediatricuse